Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Yu-Ling Ma and her team's paper "Ion Channel Targeted Mechanisms of Anti-arrhythmic Chinese Herbal Medicine Xin Su Ning" has been published in Frontiers in Pharmacology.

Yu-Ling

Xin Su Ning (XSN) is a Chinese patented and certified herbal medicine used to treat premature ventricular contractions. A newly published Ma Group study demonstrates XSN’s clinical antiarrhythmic efficacy of 12 years’ use in China without adverse reactions being officially reported.

"The method used and the standard achieved bear high quality and the clinically relevant research in cellular electrophysiology on a traditional herbal medicine aimed to illuminate its clinical antiarrythmic mechanisms." - Dr Yu-Ling Ma.

XSN is only available in China, so the team's discoveries could pave the path for translating XSN to an international standard antiarrhythmic medicine through common effort.

"Due to the multi-component nature of XSN, further studies will reveal the mechanisms of the multi-targeting action of XSN that would help to advance the latest understanding that cardiac arrhythmic diseases are multifactorial and dynamic.

Further studying the action mechanisms of XSN may also help to explain how the multicomponent action helps to reduce/eliminate the adverse reactions that single chemical antiarrhythmic drugs often possess, which has led to concerns regarding the safety of antiarrhythmic drugs used clinically." - Dr Yu-Ling Ma.

The full paper can be viewed here.

Similar stories

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Unlocking the Secrets of cAMP Signalling in the Heart: A Pathway to Targeted Therapeutics

A new Zaccolo group study has revealed key new insights into the role of cAMP signalling in both healthy and disease settings within the heart. They have identified new cAMP nanodomains in cardiac muscle cells that have far reaching implications for the treatment of heart disease.

Key exosome subtype in cancer progression identified

Collaborative work from DPAG and Oncology researchers has revealed a potential new pathway to block the production of a specific group of exosomes made in the cell’s recycling system that can promote the growth of cancerous tumours.

New blood test from DPAG cardiac researchers could save lives of heart attack victims

Researchers from the Herring group have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.